FY2026 Earnings Forecast for ARWR Issued By Leerink Partnrs

Key Points

• Arrowhead Pharmaceuticals' EPS estimates for FY2026 have been raised from ($1.57) to ($0.85) by Leerink Partners, indicating improved financial expectations.
• Despite the positive earnings forecast, the company reported a quarterly loss of ($1.26) EPS, falling short of the consensus estimate of ($0.94).
• Currently, Arrowhead Pharmaceuticals has a consensus rating of Buy from analysts, with an average target price of $43.14 for its shares.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Investment analysts at Leerink Partnrs boosted their FY2026 earnings estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Tuesday, September 2nd. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings per share of ($0.85) for the year, up from their previous forecast of ($1.57). The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals' FY2027 earnings at ($2.05) EPS and FY2028 earnings at ($1.98) EPS.

ARWR has been the subject of several other reports. Citigroup lowered their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, September 2nd. Royal Bank Of Canada lowered their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. Finally, Chardan Capital reiterated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 11th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $43.14.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ:ARWR traded up $1.08 on Friday, hitting $29.08. 2,716,522 shares of the company were exchanged, compared to its average volume of 2,920,812. Arrowhead Pharmaceuticals has a 1-year low of $9.57 and a 1-year high of $29.34. The stock's 50 day moving average price is $18.78 and its 200 day moving average price is $16.19. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $4.02 billion, a P/E ratio of -22.72 and a beta of 1.00.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million. During the same quarter last year, the firm earned ($1.38) EPS.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. grew its stake in shares of Arrowhead Pharmaceuticals by 9.7% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 27,737 shares of the biotechnology company's stock worth $438,000 after purchasing an additional 2,444 shares during the period. Marex Group plc acquired a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $576,000. State of Wyoming acquired a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $142,000. Hudson Bay Capital Management LP grew its stake in shares of Arrowhead Pharmaceuticals by 22.0% during the 2nd quarter. Hudson Bay Capital Management LP now owns 260,000 shares of the biotechnology company's stock worth $4,108,000 after purchasing an additional 46,870 shares during the period. Finally, Public Sector Pension Investment Board grew its stake in shares of Arrowhead Pharmaceuticals by 7.1% during the 2nd quarter. Public Sector Pension Investment Board now owns 428,386 shares of the biotechnology company's stock worth $6,768,000 after purchasing an additional 28,516 shares during the period. Institutional investors and hedge funds own 62.61% of the company's stock.

Insiders Place Their Bets

In related news, insider James C. Hamilton sold 15,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $25.00, for a total value of $375,000.00. Following the transaction, the insider owned 247,122 shares in the company, valued at approximately $6,178,050. This represents a 5.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 25,000 shares of company stock valued at $575,000. 4.30% of the stock is currently owned by corporate insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.